The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Pesenti S, Lauque D, Daste G, Boulay V, Pujazon MC, Carles P

Diffuse infiltrative lung disease associated with flecainide. Report of two cases.

Respiration; international review of thoracic diseases. 2002;69(2):182-5

Haas M, Pérault MC, Bonnefoy P, Rodeau F, Caron F

[Interstitial pneumopathy due to flecainide].

Presse medicale (Paris, France : 1983). 2001;30(21):1062

Stein MG, Demarco T, Gamsu G, Finkbeiner W, Golden JA

Computed tomography: pathologic correlation in lung disease due to tocainide.

The American review of respiratory disease. 1988;137(2):458-60

Feinberg L, Travis WD, Ferrans V, Sato N, Bernton HF

Pulmonary fibrosis associated with tocainide: report of a case with literature review.

The American review of respiratory disease. 1990;141(2):505-8

Hanston P, Evrard P, Mahieu P, Wallemacq P, Friob M, Hassoun A

Flecainide-associated interstitial pneumonitis.

Lancet (London, England). 1991;337(8737):371-2